

# **The Novel Antibacterial Compound Walrycin A Induces Human PXR Transcriptional Activity**

Alexandre Berthier<sup>1,2,3,4,\*</sup>, Frédéric Oger<sup>1,2,3,4,\*</sup>, Céline Gheeraert<sup>1,2,3,4</sup>, Abdel Boulahtouf<sup>5</sup>, Rémy Le Guével<sup>6</sup>, Patrick Balaguer<sup>5</sup>, Bart Staels<sup>1,2,3,4</sup>, Gilles Salbert<sup>7</sup> and Philippe Lefebvre<sup>1,2,3,4,¶</sup>

<sup>1</sup> Univ Lille Nord de France, F-59000 Lille, France

<sup>2</sup> Inserm, U1011, F-59000 Lille, France

<sup>3</sup> UDSL, F-59000 Lille, France

<sup>4</sup> Institut Pasteur de Lille, F-59019 Lille, France

<sup>5</sup> Plateforme CMT - Equipe Signalisation Hormonale, Environnement et Cancer, IRCM - Institut de Recherche en Cancérologie de Montpellier. INSERM U896 - UM1 - CRLC Val d'Aurelle - Parc Euromédecine, F-34298 Montpellier Cedex 5 France

<sup>6</sup> Plateforme ImpACcell, Génétique Fonctionnelle, Agronomie et Santé (IFR 140 GFAS), 2 Avenue du Pr. Léon Bernard CS 34317 35043 Rennes, France, Cedex

<sup>7</sup> Equipe SPARTE, UMR CNRS 6026-Université Rennes 1, Campus Beaulieu, 35042 Rennes, France, Cedex

\* These two authors contributed equally to this study.

¶ To whom correspondence should be addressed:

Philippe Lefebvre, INSERM UMR 1011-Bâtiment J&K, Université Lille-Nord de France; Faculté de Médecine de Lille-Pôle Recherche

Boulevard du Professeur Leclerc, 59045 Lille cedex, France

Tel: 33(0)3 20 97 42 20, Fax: 33(0)3 20 97 42 01

E-mail: philippe-claude.lefebvre@inserm.fr

## Abstract

The human pregnane X receptor (PXR) is a ligand-regulated transcription factor belonging to the nuclear receptor superfamily. PXR is activated by a large, structurally diverse, set of endogenous and xenobiotic compounds, and coordinates the expression of genes central to metabolism and excretion of potentially harmful chemicals and therapeutic drugs in humans. Walrycin A is a novel antibacterial compound targeting the WalK/WalR two-component signal transduction system of Gram (+) bacteria. Here we report that, in hepatoma cells, walrycin A potently activates a gene set known to be regulated by the xenobiotic sensor PXR. Walrycin A was as efficient as the reference PXR agonist rifampicin to activate PXR in a transactivation assay at non cytotoxic concentrations. Using a limited proteolysis assay, we show that walrycin A induces conformational changes at a concentration which correlates with walrycin A ability to enhance the expression of prototypic target genes, suggesting that walrycin A interacts with PXR. The activation of the canonical human PXR target gene *CYP3A4* by walrycin A is dose- and PXR-dependent. Finally, *in silico* docking experiments suggest that the walrycin A oxidation product Russig's blue is the actual a ligand for PXR. Taken together, these results identify walrycin A as novel human PXR activator.

**Keywords:** Walrycin A, Pregnane X Receptor, Nuclear Receptor, CYP3A4, Ligand Binding Domain, Xenobiotic.

## Introduction

Xenobiotics, such as drugs and environmental chemicals, exert a profound influence on human health. Xenobiotics can alter homeostasis and induce deleterious metabolic perturbations. In order to promote the metabolic inactivation and excretion of these compounds, multiple signalling pathways are activated to trigger hepatic biotransformation, biliary excretion and renal elimination. Part of these clearance mechanisms are coordinately controlled by nuclear receptors such as Pregnane X Receptor (PXR/NR1I2) and Constitutive Androstane Receptor (CAR/NR1I3). Being important transcription factors controlling xenobiotic detoxification, CAR and PXR display a strong expression in the primarily exposed organs, the liver and the intestine (Lamba *et al.* 2004; Savkur *et al.* 2003).

As many nuclear receptors, CAR and PXR possess a conserved DNA Binding Domain (DBD) and a variable C terminal Ligand Binding Domain (LBD). Within the LBD, the ligand-binding pocket of CAR and PXR accommodate a wide range of structurally unrelated endogenous and exogenous ligands (di Masi A. *et al.* 2009). For instance, human PXR and human CAR are both activated by endogenous ligands such as bile acids and steroid hormones (Guo *et al.* 2003; Timsit and Negishi 2007; Xie *et al.* 2003), xenobiotics such as drugs (e.g. rifampicin, dexamethasone and phenobarbital), endocrine disrupters (bisphenol A, phthalates) and natural plant compounds (hyperforine, zearalenone) (Ayed-Boussema *et al.* 2011; DeKeyser *et al.* 2011; Lehmann *et al.* 1998; Moore *et al.* 2000; Sueyoshi *et al.* 1999).

Through their DBD, CAR and PXR bind to various response elements (direct repeats DR3, DR4 and DR5 as well as everted repeats ER6 and ER8), thereby controlling the expression of a large set of target genes involved in energy metabolism and hormone homeostasis, inflammation, cell differentiation, bile acids and bilirubin detoxification (Moreau *et al.* 2008; Pascussi and Vilarem 2008; Wada *et al.* 2009). Moreover, this versatile

DNA binding property allows cross talks between CAR and PXR, and also with other nuclear receptors such as FXR, LXR, VDR, PPAR, ER, GR, COUP-TFI and II (Breuker *et al.* 2010; di Masi A. *et al.* 2009; Faucette *et al.* 2006; Ihunnah *et al.* 2011; Istrate *et al.* 2010).

PXR and CAR have been initially described as xenobiotic sensors modulating the expression of several hepatic target genes driven by a so-called "xenobiotics response element" and involved in detoxification pathways, including drug-metabolizing enzymes and transporters (Omiecinski *et al.* 2011; Wada *et al.* 2009). For instance, human cytochrome P450 2B6 (*CYP2B6*) and 3A4 (*CYP3A4*) expression is under the control of CAR and PXR respectively (Kliewer *et al.* 2002; Lehmann *et al.* 1998; Maglich *et al.* 2003; Mo *et al.* 2009; Sueyoshi *et al.* 1999). The *CYP3A* sub-family member *CYP3A4* is a key player in detoxification pathways, since about 50% of therapeutically used drugs are metabolized by this enzyme (Istrate *et al.* 2010; Kliewer *et al.* 2002). Moreover, the PXR/*CYP3A4* pathway is involved in 60% of known drug-drug interactions (Evans 2005). Rifampicin, an antibiotic used to treat tuberculosis as well as nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* (MRSA) is a human PXR agonist inducing *CYP3A4* expression. *CYP3A4* metabolizes more than 100 drugs including oral contraceptives, anti-HIV protease inhibitors (Baciewicz *et al.* 2008; Ivanovic *et al.* 2008; Ma *et al.* 2008) and antibiotics, (Jung *et al.* 2010). Thus, activation of the PXR signalling pathway leads to a diminished therapeutic efficacy of many drugs and also potentially produces toxic metabolites. There is therefore a need to determine the effects of each novel therapeutic compound on PXR activity.

Recently, a novel antibacterial compound called walrycin A (4-methoxy-1-naphthol) has been identified through a high throughput screening approach and shown to target the WalK/WalR two-component signal transduction system of Gram (+) bacteria such as *Staphylococcus aureus* and *Bacillus subtilis* (Gotoh *et al.* 2010). Given that walrycin A belongs to a potential novel class of antibacterial compounds, effects on human xenobiotics

metabolism and hepaotoxicity remain to be studied. Here we report that walrycin A modulates human PXR activity and impacts on hepatic cell viability.

## Materials and Methods

### Materials

Rifampicin, 6-methoxy-1-naphtol (6MNol) and 4-methoxy-1-naphtol (walrycin A), purchased from Sigma-Aldrich (St-Louis, MO, USA) were dissolved in dimethylsulfoxide (DMSO). The housekeeping gene ribosomal protein large P0 (*RPLP0*, NM\_001002.3) forward (CATGCTCAACATCTCCCCCTTCTCC) and reverse (ATGCAGCCCCGAATGCTCCTCATCGTGGCC) primers, *CYP3A4* (NM\_017460.5) forward (CATTCCTCATCCCAATTCTTGAGGT) and reverse (CCACTCGGTGCTTTTGTGTATCT) primers and *PXR* isoforms 1 (NM\_003889.3) and 2 (NM\_022002.2) forward (ACCTTTGACACTACCTTCTCCCAT) and reverse (CGCAGCCACTGCTAAGCA) primers were purchased from Sigma-Aldrich (St Quentin-Fallavier, France)

### Cell culture and treatment

The immortalized human hepatocyte (IHH) cell line was established by F. Kuipers (University Medical Center, Groningen, Netherlands) from primary human hepatocytes. Cells were routinely maintained as previously described (Schippers *et al.* 1997). Twenty-four hours before treatment, cells were seeded ( $3 \cdot 10^5$  cells per well) in 12-well plates in seeding medium (phenol-red free Dulbecco's Modified Eagle Medium (DMEM) supplemented with 2 g/L glucose, 2 mM glutamine (Invitrogen Life Technologies, Carlsbad, CA, USA), 7 µg/mL bovine insulin (Sigma-Aldrich), 100 U/mL penicillin (Invitrogen), 100 µg/mL streptomycin (Invitrogen) and 10 % charcoal dextran-stripped fetal calf serum (CD-FCS). Cells were washed once before treatment with stimulating medium (seeding medium with CD-FCS reduced to 1%) and treated for 24 h by compounds at indicated concentrations (0.1% DMSO final concentration).

### **qPCR-based array**

First Strand cDNA Synthesis Kit and Human Drug Metabolism RT<sup>2</sup>Profiler™ PCR Arrays were purchased from SABiosciences (SABiosciences, Frederick, MD, USA). Both reverse transcription and qPCR (Stratagen Mx3005P QPCR System) were performed following manufacturer's instructions. Five endogenous control genes –  $\beta$ -2-microglobulin (*B2M*), hypoxanthine phosphoribosyltransferase (*HPRT1*), ribosomal protein L13a (*RPL13A*), glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), and  $\beta$ -actin (*ACTB*) - displayed on the PCR array were used for normalization. Cycle threshold (Ct) was normalized to the average Ct of these 5 endogenous controls. The comparative Ct method was used to calculate the relative quantification of gene expression (Livak and Schmittgen 2001). The following formula was used to calculate the relative amount of the transcripts in the walrycin A and vehicle (DMSO) treated sample, both of which were normalized to the endogenous controls:  $\Delta\Delta Ct = \Delta Ct (\text{walrycin A}) - \Delta Ct (\text{DMSO})$ .  $\Delta Ct$  is the log<sub>2</sub> difference in Ct between the target gene and the average Ct of the five endogenous controls. The fold change for walrycin A-treated sample is expressed relative to the control (DMSO) sample =  $2^{-\Delta\Delta Ct}$ .

### **Cell transfection**

IHH cells were seeded 24 hours before transfection in 6-well plates ( $10^6$  cells per well) in maintenance medium (Schippers *et al.* 1997). Cells were transfected using 0.1 nmol of ON-TARGETplus SMARTpool hPXR siRNA or non-targeting siRNA using the Dharmafect1 transfection reagent according to the manufacturer's protocol (Thermo Fisher Scientific, Lafayette, CO, USA). After a 24 h incubation, cells were washed with seeding medium and incubated further for 24 h. Cells were then washed with stimulating medium and treated as described above.

### **RNA extraction, reverse transcription and real time qPCR**

At indicated times, cells were washed with 1x phosphate buffer saline (1x PBS) and total RNA was extracted using the Extract-all reagent (Eurobio, Courtabeuf, France) according to the manufacturer's protocol. One  $\mu\text{g}$  of total RNA was reverse-transcribed using the High Capacity Reverse Transcription Kit (Applied Biosystem, Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. A 1:20 dilution of cDNA was then amplified by real time qPCR using Brilliant II Fast SybR Green Master Mix (Agilent Technologies, Santa Clara, CA, USA) and specific primers in a Stratagen Mx3005P QPCR System (Agilent Technologies). Gene expression levels were normalized using the *RPLP0* housekeeping gene expression level as internal control. Fold induction were expressed as the ratio of the gene induced expression level to that of the basal level arbitrarily set to one.

### **Western blotting**

At indicated times, transfected cells were washed with 1x PBS followed by total protein extraction using 100  $\mu\text{L}$  of Cell Lysis Buffer (Cell Signaling Technology, Beverly, MA, USA) according to the manufacturer's protocol. Western blotting was performed using 40  $\mu\text{g}$  of total proteins. hPXR protein expression was monitored using an anti-hPXR mouse monoclonal antibody (Perseus Proteomics Inc, Tokyo, Japan) and a HRP-conjugated goat anti-mouse secondary antibody (Sigma-Aldrich). The immune complexes were detected by chemiluminescence using Pierce ECL-plus Western Blotting Substrate (Thermo Fisher Scientific) according to the manufacturer's protocol and visualized with a G:Box gel dock system (Syngene, Cambridge, UK). HSP90 protein was used as internal standard for equal loading using a rabbit anti HSP90 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) and a HRP-coupled goat anti rabbit as secondary antibody (Sigma-Aldrich).



### **Limited proteolysis assay**

*In vitro* translation of hPXR was performed using the TNT T7 Quick Coupled Transcription/Translation System (Promega, Madison, WI, USA) and the [<sup>35</sup>S]-containing Protein Labelling Mix Easy Tag (Perkin Elmer, Waltham, MA, USA), in the presence of vehicle (0.1% DMSO), 50 μM walrycin A, 50 μM rifampicin or 50 μM 6MNol following the supplier's instructions. Limited proteolysis of the radiolabeled receptor (5 μL of TnT mix) was carried out using increasing concentrations of chymotrypsin ranging from 1 to 5 μg/mL. After a 10 min. incubation, digestion was stopped by the addition of 6X Laemmli buffer. Samples were boiled for 5 min. and separated by 12% SDS-PAGE. After gel drying, radiolabeled digestion products were visualized using a STORM Phosphorimager (GE Healthcare, Orsay, France).

### **Gene reporter assay**

The stable reporter cell line HGPXR stably expressing a GAL4DBD-hPXR LBD chimeric fusion protein was described previously (Lemaire *et al.* 2006).

### **Methods for computer-simulated ligand binding (docking)**

**Protein input files preparation.** Ligand-free PXR (1ILH.pdb and 3HVL.pdb) input files were generated using the protein preparation wizard from the Maestro software (Maestro 8.5, Academic Campaign, <http://www.schrodinger.com>). The bond orders were assigned and hydrogen atoms were added. The resulting receptor coordinates were saved as a pdb file.

**Ligand input files preparation.** Ligand input structures were generated and 3D-optimized with the MarvinSketch Academic Package (MarvinSketch 5.4.1.1, 2011, ChemAxon <http://www.chemaxon.com>). Ligand structures were saved as mol2 files.

**GOLD and FRED docking protocol.** Docking was performed using chemscore fitness function under standard default settings in the GOLD software (Cambridge Crystallographic Data Centre 12 Union Road, Cambridge, CB2 1EZ, UK, <http://www.ccdc.cam.ac.uk>): search efficiency: 200%, population size 100, number of islands 5, number of operations 100,000, niche size 2, migrate 10, mutate 95, cross over 95 and a selection pressure of 1.1. Early termination was allowed if 4 solutions were within 1.5 angstroms of root mean square deviation (RMSD). Docking with FRED 2.2.5, (OpenEye Scientific Software, Inc., Santa Fe, NM, USA, [www.eyesopen.com](http://www.eyesopen.com), 2011) was performed using Chemgauss3 scoring for exhaustive search and Chemgauss3 scoring for optimization.

### **Viability assays**

HepG2 cells were seeded in 96-well plates ( $10^4$  cells per well) in maintenance medium and incubated for 24 hours. Cells were treated for 24 h with indicated concentrations of compounds. Cell viability was quantified using the CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer's protocol. Absorbance was monitored on MRX spectrophotometer (Thermo Labsystems, Issy Les Moulineaux, France). Results were calculated as follows:  $(A_{570} - A_{630})_{\text{compound}} / (A_{570} - A_{630})_{\text{DMSO}}$ . Curve fitting was performed using GraphPad Prism 4.0 software (San Diego, CA, USA). Each concentration was tested in quadruplicate and data are displayed as means  $\pm$  SEM.

### **Statistical Analysis**

Histograms represent means  $\pm$  SEM (n=2-3). Statistical analyses were performed using GraphPad Prism 4.0. Statistical significance was determined using a one-way ANOVA followed by a Dunnett's multiple comparison post-hoc test (p-values < 0.01 were considered as

significant). For knock-down assays, significant differences were determined using a two-way ANOVA followed by a Bonferroni post-hoc test.

## Results

### **Walrycin A regulates mRNA expression of genes involved in phase I drug metabolism.**

Walrycin A harbors potent antibacterial activity against the methicillin-resistant *S. aureus* (MRSA) strain N315 (Gotoh *et al.* 2010). Since rifampicin displays a similar efficacy against MRSA (Perlroth *et al.* 2008) and induce drug metabolizing enzymes in human hepatocytes at a concentration of ~30-50  $\mu\text{M}$  (Rae *et al.* 2001), we first assessed whether walrycin A could modulate the expression of enzymes involved in drug/xenobiotic metabolism pathway at a similar concentration. Since drug metabolism is initiated upon the activation of phase I enzymes, we focused our analysis on this class of enzymes using qPCR macroarrays. Human immortalized hepatocytes [IHH cell line, (Schippers *et al.* 1997)] were treated for 24 hours by 50  $\mu\text{M}$  walrycin A and 0.1% DMSO as a control. The differential mRNA expression analysis of 83 phase I enzymes was monitored and analyzed using a fold change cut-off of 4. This allowed the identification of 31 upregulated (36.9 %), and of only 2 downregulated (2.4 %) genes (Figure 1B). The expression of 50 genes were not affected (59.5 %) (Supplementary figure S1). Walrycin A-modulated genes could be classified into 3 main classes of enzymes (alcohol dehydrogenases, aldehyde dehydrogenases and cytochrome p450s). Genes encoding proteins with other functions, such as *FMO1*, are displayed as “Others” (Figure 1C). Very interestingly, the PXR target genes *CYP1A1* and *CYP3A4* were strongly upregulated (30.9 and 5.2 fold respectively) in response to walrycin A. Given that both drug-activated CAR and PXR may equally regulate the expression of genes in human

hepatocytes such as *CYP1A1* and *CYP3A4* (Auerbach *et al.* 2007; Faucette *et al.* 2006), we determined the relative expression of mRNAs coding for these two nuclear receptors in IHH cells. As *PXR* mRNA was strongly expressed whereas *CAR* mRNA was not detectable (see Supplementary figure S2), this indicated that the observed altered gene expression pattern upon walrycin A treatment could result from PXR activation. In addition, this indicated that IHH cells provide a valid experimental model to evaluate specific PXR response upon exposure to xenobiotics.

### **Dose-dependent activation of *CYP3A4* by walrycin A is PXR-dependent.**

We further assessed the contribution of PXR to the observed alteration of the gene expression pattern. IHH cells were treated in parallel for 24 hours with the PXR reference agonist rifampicin or walrycin A or the walrycin A structural analogue 6MNol. As expected, rifampicin induced *CYP3A4* mRNA expression in a dose-dependent manner (Figure 2A) with an  $EC_{50} \sim 1 \mu\text{M}$  reaching a plateau starting at  $10 \mu\text{M}$  (4-fold maximal induction). Interestingly, *CYP3A4* mRNA expression was also enhanced in a dose-dependent manner by walrycin A, with a maximal induction reached at  $100 \mu\text{M}$  and an  $EC_{50} \sim 30 \mu\text{M}$  (Figure 2B). 6MNol was inactive in this assay. Taken together, these results indicate that walrycin A activates signalling pathway(s) controlling *CYP3A4* mRNA expression.

We then hypothesized that walrycin A-induced *CYP3A4* mRNA expression was PXR-dependent. To assess this possibility, *PXR* knock-down was performed in IHH cells using siRNAs (Figure 2C and 2D). Both *PXR* mRNA and protein were significantly downregulated upon anti-PXR siRNA treatment (Figure 2C), whereas a non-specific siRNA did not affect *PXR* expression. *CYP3A4* mRNA was induced upon rifampicin treatment, whereas *PXR* knock-down significantly blunted this response (Figure 2D). Importantly, walrycin A-induced *CYP3A4* mRNA expression was decreased upon *PXR* knock-down, but not affected by the

non-specific siRNA (Figure 2D). Thus, induction of *CYP3A4* expression in response to walrycin A is a PXR-dependent process .

### **Walrycin A interacts with PXR and modifies its conformation.**

As we demonstrated that the induction of *CYP3A4* by walrycin A is PXR-dependent, we next hypothesized that walrycin A could directly interact with PXR. To assess this possibility, limited proteolysis experiments were performed to probe potential structural modifications of the PXR polypeptide upon walrycin A binding. Full-length PXR was translated *in vitro* using <sup>35</sup>S-labelled methionine in the presence of either DMSO (negative control), rifampicin (positive control), walrycin A or the related compound 6MNol. Unliganded and liganded PXR were then submitted to limited proteolysis using increasing concentrations of chymotrypsin ranging from 0.5 µg/mL to 5 µg/mL (Figure 3). Full-length radiolabeled PXR protein was more amenable to degradation by chymotrypsin in the presence of rifampicin compared to negative control (1% DMSO), leading to several proteolysis resistant peptides (Figure 3). The PXR proteolysis pattern in the presence of walrycin A was totally different to that induced by DMSO, suggesting that walrycin A, like rifampicin, interacts with PXR and modifies its conformation, hence exposing chymotrypsin cleavage sequences. The digestion pattern generated in presence of 6MNol was comparable to that observed in the presence of DMSO, indicating that this compound is unlikely to bind PXR. These results are in line with the (lack of) effect of these compounds on PXR-mediated induction of *CYP3A4* expression.

### **Walrycin A activates PXR through its ligand binding domain.**

Since protease-resistant fragments observed in limited proteolysis assays can be attributed to structural alterations occurring in the LBD of nuclear receptors (Benkoussa *et al.*

1997), our limited proteolysis assays strongly suggested that walrycin A modulates PXR activity through interaction with the PXR LBD. To verify this hypothesis, a luciferase gene reporter assay was performed using a modified HeLa cell line (HGPR cells) in which a chimeric GAL4 DBD-hPXR LBD fusion protein is stably expressed (Lemaire *et al.* 2006; Lemaire *et al.* 2007). HeLa cells were treated with concentrations of walrycin A ranging from 0.5  $\mu\text{M}$  to 500  $\mu\text{M}$ , and the luciferase activity was monitored (Figure 4A). This system was not sensitive to walrycin A concentrations below 5  $\mu\text{M}$ . Nonetheless, a dose-dependent increase in the luciferase activity was observed starting at 5 $\mu\text{M}$  and reached a maximum at approximately 150  $\mu\text{M}$ , with a calculated  $\text{EC}_{50} \sim 10 \mu\text{M}$ . To evaluate PXR selectivity for walrycin A or 6MNol, an independent experiment was performed in the same system using 150  $\mu\text{M}$  of walrycin A or of 6MNol. As shown in Figure 4B, walrycin A significantly enhanced luciferase transactivation when used at 150  $\mu\text{M}$  when compared to vehicle (DMSO), up to a level close to 80% of the maximal response obtained with the reference PXR ligand SR12813 (Moore *et al.* 2000), whereas 6MNol was again inactive. Taken together, these results show that walrycin A activates PXR through its LBD and is likely to be a novel ligand for this nuclear receptor.

### **The walrycin A oxidation product Russig's blue is efficiently docked into the PXR LBD.**

Having shown that walrycin A can alter PXR conformation *in vitro* and activates PXR through its LBD in cellular assays, we next analyzed the ability of walrycin A, of the closely related molecule 6MNol, and of Russig's blue, an oxidation product of walrycin A (Shoji *et al.* 2010), to fit in the ligand-binding pocket of PXR by *in silico* docking experiments. Docking was first implemented using PXR LBD coordinates extracted from the 3hvl.pdb file, corresponding to a human PXR LBD crystal obtained in the presence of a short SRC-1 coactivator peptide and of the bound synthetic PXR agonist SR12813 (Watkins *et al.* 2001).

As shown in Figure 5A, SR12813 was efficiently docked by our procedure with solutions mostly superposable to the 3HVL coordinates (Watkins *et al.* 2001). Walrycin A and 6MNol docked perpendicular to the phenyl ring of SR12813, leaving most of the ligand-binding pocket empty (Figure 5A). In contrast, Russig's blue positioned similarly to SR12813 (Figure 5B). Ranking ligand fit in 3HVL showed that Russig's blue has the highest score compared to walrycin A and 6MNol, using either GOLD or FRED softwares (Figure 5B). Similar conclusions were drawn when using other PXR LBD coordinates (1ILH), corresponding to the human PXR LBD co-crystallized with SR12813 but without a coactivator peptide (data not shown). These data suggest that walrycin A may dock into the PXR LBD in its oxidized form Russig's blue.

#### **Walrycin A and hepatic cells viability.**

Rifampicin and walrycin A share common bactericidal properties, raising the possibility of a combined antibacterial therapy. We therefore investigated the effect of walrycin A alone or in combination with rifampicin on the viability of human hepatoma cell lines IHH and HepG2. Cell viability assays were performed using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) as a substrate for mitochondrial reductase. To assess walrycin A toxicity, cells were independently exposed for 24 h to walrycin A and 6MNol concentrations increasing from 2  $\mu$ M up to 5 mM, whereas rifampicin concentrations were from 0.5 $\mu$ M to 1 mM. Walrycin A concentrations up to 156  $\mu$ M did not affect HepG2 viability (Figure 6A). Walrycin A  $IC_{50}$  was calculated to be 240  $\mu$ M, indicating that this compound impacted cell viability at a concentration lower than that of rifampicin [ $IC_{50}$ ~1 mM, Figure 6A and (Nakajima *et al.* 2011)] and 6MNol ( $IC_{50}$ ~1.7 mM, data not shown). Similar results were obtained using IHH cell line ( $IC_{50}$  walrycin A~350  $\mu$ M,  $IC_{50}$  rifampicin~4.5 mM,  $IC_{50}$  6MNol~1.8 mM, data not shown).

The potential synergy between walrycin A and rifampicin was then assessed in the MTS assay. HepG2 cells were exposed to increasing concentrations of rifampicin (from 3  $\mu\text{M}$  to 100  $\mu\text{M}$ ) with or without 50  $\mu\text{M}$  walrycin A for 24 or 48 hours (Supplementary figure S4). Highest rifampicin and walrycin A concentrations (100  $\mu\text{M}$  and 50  $\mu\text{M}$  respectively) did not impact cell viability after the 24 h exposure, whereas the combined walrycin A/rifampicin treatment significantly decreased cell viability by approximately 35 % (Figure 6B, left panel). After a 48 h exposure, HepG2 cell viability was significantly decreased upon rifampicin (100  $\mu\text{M}$ ) treatment when compared to walrycin A (50  $\mu\text{M}$ ) treatment, corroborating data from (Singh *et al.* 2011). The combined walrycin A/rifampicin exposure for 48 hours significantly decreased cell viability by approximately 50 % when compared to rifampicin alone (Figure 6B, right panel). Similar results were obtained by exposing HepG2 cells to increasing concentrations of walrycin A (from 3  $\mu\text{M}$  to 100  $\mu\text{M}$ ) together with rifampicin 10  $\mu\text{M}$  (Supplementary figure S4). Taken together, these results indicated that rifampicin and walrycin A synergistically impacted human hepatoma cell viability in a dose- and time-dependent manner.



## Discussion

Bacterial infections, despite intense efforts to thwart them, remain a major public health problem not only in developing but also in occidental countries, as highlighted by the reminiscence of nosocomial infections. Methicillin-resistant *Staphylococcus aureus* (MRSA) is a widespread nosocomial pathogen (Diekema *et al.* 2001) resistant to  $\beta$ -lactam antibiotics, cephalosporins and to the last resort antibiotic vancomycin, to which 40% of MRSA infected patients are resistant (Jeffres *et al.* 2006; Rello *et al.* 1994). Therefore, given the high mortality rates caused by these drug-resistant bacteria and the difficulty to develop novel potent and specific antibiotics targeting these bacterial pathogens, combined antibactericidal treatments are currently used to kill increasingly common antibiotic resistant-strains. Rifampicin harbors valuable properties in combination with first-line antibiotics, and the combination of rifampicin and vancomycin is an effective treatment against nosocomial MRSA-induced pneumoniae (Jung *et al.* 2010). The novel antibacterial compound walrycin A is effective against the MRSA *S. aureus* N315 strain (Gotoh *et al.* 2010; Kuroda *et al.* 2001), suggesting that it could be successfully used in combination with other antibiotics such as rifampicin, since its high minimal inhibitory concentration on MRSA (734 $\mu$ M) precludes its use as a standalone therapy.

However, drug-drug interactions induced upon antibiotics (co)treatment may lead to increased cytotoxicity as exemplified by liver damage, and to reduced efficiency due to rapid drug inactivation resulting from the activation of the nuclear xenobiotic sensors CAR and PXR (Singh *et al.* 2011). Evaluating the activity of walrycin A on hepatic functions is therefore critical to evaluate its potential usefulness as an anti-MRSA drug.

The structure of walrycin A is based on a naphthalen scaffold, conferring hydrophobic properties, substituted by alcohol and methoxy functions in position 1 and 4 respectively. As described by Gotoh *et al.*, walrycin A targets the WalK/WalR two-component signal transduction system of Gram (+) bacteria, indicating that this compound gets effectively through the bacterial peptidoglycanic wall and cytoplasmic membrane of prokaryotes (Gotoh *et al.* 2010). Therefore, walrycin A could pass through the eukaryote plasma membrane to activate various signalling pathways, including those controlled by PXR. Indeed, walrycin A was found to induce the expression of several PXR target genes such as the drug metabolism phase I enzymes *CYP1A1/1A2/2B6/2C8/2C19/3A4/11A1/11B1/11B2* (di Masi A. *et al.* 2009) and *CYP4A11* (Siest G. *et al.* 2008). Walrycin A also deregulated the expression of several enzymes not identified as PXR target genes, suggesting that walrycin A modulates other non identified signalling pathways.

The PXR-*CYP3A4* pathway is involved in approximately 60% of reported drug-drug interactions (Evans 2005). *CYP3A4* mRNA expression was enhanced in a PXR-dependent manner upon walrycin A treatment. Owing to its structure, walrycin A can potentially activate PXR through direct binding or by triggering post-translational modifications of this nuclear receptor. To sort out these non-exclusive hypotheses, we investigated whether walrycin A is a direct activator of PXR. Using *in vitro* limited proteolysis and gene reporter assays, we demonstrated that walrycin A is likely to act through the PXR LBD. However, *in silico* docking of walrycin A into the PXR ligand binding pocket revealed that the walrycin A oxidation product, Russig's blue, is more likely to behave as a bona-fide PXR ligand. This is consistent with the fact that walrycin A spontaneously oxidizes in various aqueous solutions (Shoji *et al.* 2010 and our unpublished observations), and with the strict stereoselectivity of PXR activation, on which the structurally related 6MNol is inactive and unable to convert into a spectrally detectable compound (our unpublished observations).

Activation of PXR is known to be species-specific, and several reports document the irrelevance of rodent models for assessing the ability of xenobiotics to regulate human PXR activity (Jones *et al.* 2000; Lecluyse 2001; Ma *et al.* 2007). Importantly, the expression of mouse Cyp3a family members is not altered upon administration of rifampicin (Ma *et al.* 2007) in contrast to dexamethasone, a known mouse PXR activator (Scheer *et al.* 2010). Our *in vitro* transactivation assays established that walrycin A is an activator of human, but not of mouse PXR (Supplementary figures S3A and S3B). In line with these results, orally administered walrycin A (200 mg/kg) for eight days to C57Bl6 mice neither induced the expression of *Cyp3a11*, the mouse orthologue of human *CYP3A4*, nor caused significant macroscopic liver damage (data not shown). This clearly suggested that walrycin A is unable to activate mouse PXR. Our data and others (Ma *et al.* 2007) thus underline the need for humanized-PXR mouse models to study the *in vivo* effects of walrycin A and other antibiotics rather than wild-type mice.

CAR also plays a major role in drug biotransformation pathways by regulating the expression of, among others, *CYP2B*, *CYP2C*, *CYP3A*, *UGTs*, *GSTs* and membrane transporters *MRP2&4* (di Masi A. *et al.* 2009; Omiecinski *et al.* 2011). It is therefore important to investigate the effects of walrycin A on CAR activity. Our data indicates that walrycin A behaves, like many CAR modulators, as an inverse agonist of CAR1 (Supplementary figure S5). Up to 15 CAR isoforms are expressed in human liver (Lamba *et al.* 2004) and some compounds, such as clotrimazole, display opposite modulatory properties on CAR1 and CAR3 isoforms (Auerbach *et al.* 2005; Moore *et al.* 2000). This highly complex signalling system, which does not occur in IHH and HepG2 hepatoma cell lines, does not allow an easy prediction of biological outcomes following CAR activation in the liver, and certainly deserves further investigation.

In addition to its PXR and CAR modulatory effects, walrycin A exhibited weak cytotoxic properties on human hepatoma cells, but synergistically increased rifampicin toxicity and vice-versa. This suggests that a combination of rifampicin and walrycin A could induce deleterious hepatic effects *in vivo*. This drawback has also been reported for the vancomycin/rifampicin combined treatment (Jung *et al.* 2010), which is likely due at least in part to drug-drug interactions. Finally, we noted that some walrycin A-exposed mice exhibited a marked splenomegaly, in agreement with a study in rats (Eastman Kodak Co. *et al.* 1992), and which might stem also from a portal hypertension secondary to liver disease. The design of efficient antibiotics thus comes up against important problems of hepatotoxicity and of hepatic xenobiotic sensors regulation.

Finally, to the best of our knowledge, walrycin A is not yet validated as a therapeutically usable drug and there is therefore no information on human exposure level. Nevertheless, as this compound and/or its derivative Russig's blue activate PXR and CAR, hepatic effects of a simultaneous exposure to walrycin A and to other drugs should be considered in the future. As walrycin A is also a widely used compound in chemical synthesis (Talaat and Nelson 1986), the effects of a fortuitous acute or chronic exposition should be monitored in workers exposed to this compound, especially since combined, unwanted exposure to other environmental pollutants such as phthalates and bisphenol A, also known to activate human PXR and CAR (DeKeyser *et al.* 2011), can dangerously impact health (Howdeshell *et al.* 2007).

## Supplementary informations

### Supplementary materials and methods

#### Materials

Reporter vector (pDR4-tk-*LUC* vector) was produced by inserting three direct repeats 4 (DR4, 3X-agggtcacaggagggtca) into a p-tk-*LUC* vector. The human PXR cDNA was subcloned into a pSG5 vector. Expression vectors pSG5-mPXR and pSG5-hRXR $\alpha$  were kindly provided by Pr. Steven Kliewer (Southwestern Medical Center, Dallas, TX, USA) and Pr. Hugues De Thé (Inserm U944, Paris, France) respectively. The expression vector pHA-hCAR1 and the normalisation vector (pRL-CMV) were purchased from Genecopoeia (Rockville, MD, USA) and Promega respectively. Human CAR1 agonist 6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO) and inverse agonist 5 $\alpha$ -Androst-16-en-3 $\alpha$ -ol (Androst-enol) purchased from Sigma-Aldrich were dissolved in DMSO.

#### CAR and PXR mRNA expression

End-point PCR was performed using cDNA prepared from IHH cells RNA. Primers used allowed either amplification of 15 CAR isoforms (Lamba *et al.* 2004) or PXR isoforms 1 and 2. Reactions were performed using GoTaq Flexi DNA polymerase (Promega) according to the manufacturer's protocol.

#### Walrycin A effect on human CAR and mouse PXR activities

HepG2 cells were maintained in MEM medium (Invitrogen) supplemented with 2 g/L glucose, 2 mM glutamine, 100 U/mL penicillin, 100  $\mu$ g/mL streptomycin, 100  $\mu$ M non essential amino acids (Invitrogen), 1 mM pyruvate (Invitrogen) and 10 % fetal calf serum

(Lonza, Levallois-Perret, France). Twenty-four hours before transfection, cells were seeded in 6cm- plates ( $2,5 \cdot 10^6$  cells) in HepG2 maintenance medium. HepG2 were transfected by 4  $\mu\text{g}$  reporter vector (pDR4-tk-*LUC*), 0.5  $\mu\text{g}$  of expression vector (pSG5-h*PXR*, pSG5m*PXR* or pHA-h*CAR1*), 0.5  $\mu\text{g}$  of pSG5-h*RXR* $\alpha$  expression vector and 0.6  $\mu\text{g}$  of normalization vector (pRL-CMV) using 11  $\mu\text{l}$  of Jet PEI transfection reagent. Twenty four hours after transfection, cells were seeded in 96-well plates ( $20 \cdot 10^3$  cells per well) in seeding medium and incubated 24 hours. Cells were washed once before treatment with stimulating medium and treated for 24 h by compounds at indicated concentrations (0.1% DMSO final concentration). At the end of treatment, luciferase and renilla activities were determined using the Dual-Glo Luciferase assay system (Promega) and a Victor Light 1420 luminescence counter (Perkin Elmer, Waltham, MA, USA) according to the manufacturer's protocol.

#### **Effects of co-treatments on HepG2 viability.**

HepG2 cells were seeded in 96-well plates ( $5 \cdot 10^4$  cells per well) in maintenance medium and incubated for 24 hours. Cells were treated for 24 h or 48 h with rifampicin concentrations ranging from 3  $\mu\text{M}$  to 100  $\mu\text{M}$  alone or in combination with 50  $\mu\text{M}$  walrycin A. In a similar manner, HepG2 cells were treated for 24 h or 48 h with walrycin A concentrations ranging from 12  $\mu\text{M}$  to 400  $\mu\text{M}$  alone or in combination with 10  $\mu\text{M}$  rifampicin.

#### **Legend to supplementary Figures**

**S1: List of unregulated genes expression (fold-change 4) in response to walrycin A treatment.** Genes are classified in four groups: alcohol dehydrogenase, aldehyde dehydrogenase, cytochrome p450 and “others”.

**S2: CAR mRNA is not expressed in IHH cells.** CAR isoforms 1, 2 and 3 (main isoforms expressed in liver) mRNA were not detected after 40 amplification cycles (upper panel) whereas PXR mRNA was detected from 30 amplification cycles (lower panel). PCR internal controls were performed using plasmids containing cDNA encoding hCAR1, hCAR2, hCAR3 and hPXR.

**S3: Walrycin A specifically activates the human PXR.** HepG2 cells were co-transfected by reporter vector under control of a DR4 response element and either (A) a human PXR expression vector or (B) a mouse PXR expression vector. Cells were treated with vehicle (DMSO, negative control), walrycin A, 6MNol, rifampicin (positive control for hPXR) or dexamethazone (positive control for mPXR). Histograms represent means  $\pm$  SEM of a representative experiment performed in triplicate. Statistical significance was determined using a Dunnett's Multiple Comparison Test (\* $p < 0.05$ , \*\* $p < 0.01$ ).

**S4: The rifampicin/walrycin A co-treatment increases toxicity in human hepatoma cells.** HepG2 cells were treated for 24h (A) or 48h (B) with increasing concentrations of rifampicin alone (black lines) or in combination with walrycin A 50  $\mu$ M (grey lines). HepG2 cells were treated for 24h (C) or 48h (D) with increasing concentrations of walrycin A alone (gray lines) or in combination with rifampicin 10  $\mu$ M (black lines).

**S5: Walrycin A harbors inverse agonist properties on human CAR1 activity.** HepG2 cells were co-transfected by the reporter gene under the control of a DR4 response element (p-DR4-tk-LUC) and a hCAR1 expression vectors. After transfection, cells were treated by vehicle (DMSO), walrycin A, 6MNol, CITCO (positive control) alone or in presence of androstenol (hCAR inverse agonist). Histograms represent means  $\pm$  SEM of a representative

experiment performed in triplicate. Statistical significance was determined using a Dunnett's Multiple Comparison Test ( $p < 0.001$ ).

### **Funding information**

This work was supported by an unrestricted research grant from Technologie Servier (A.B.).

F.O. and C.G. were supported by OSEO-ANVAR IT-DIAB.



## **Acknowledgments**

We thank Dr. Jérôme Eeckhoutte for help with the writing of the manuscript.

## References

- Auerbach, S. S., DeKeyser, J. G., Stoner, M. A., and Omiecinski, C. J. (2007). CAR2 displays unique ligand binding and RXRalpha heterodimerization characteristics. *Drug Metab Dispos.* **35**(3), 428-439.
- Auerbach, S. S., Stoner, M. A., Su, S., and Omiecinski, C. J. (2005). Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). *Mol Pharmacol.* **68**(5), 1239-1253.
- Ayed-Boussema, I., Pascussi, J. M., Maurel, P., Bacha, H., and Hassen, W. (2011). Zearalenone activates pregnane X receptor, constitutive androstane receptor and aryl hydrocarbon receptor and corresponding phase I target genes mRNA in primary cultures of human hepatocytes. *Environ. Toxicol. Pharmacol.* **31**(1), 79-87.
- Baciewicz, A. M., Chrisman, C. R., Finch, C. K., and Self, T. H. (2008). Update on rifampin and rifabutin drug interactions. *Am. J. Med. Sci.* **335**(2), 126-136.
- Benkoussa, M., Nomine, B., Mouchon, A., Lefebvre, B., Bernardon, J. M., Formstecher, P., and Lefebvre, P. (1997). Limited proteolysis for assaying ligand binding affinities of nuclear receptors. *Recept. Signal. Transduct.* **7**(4), 257-267.
- Breuker, C., Moreau, A., Lakhil, L., Tamasi, V., Parmentier, Y., Meyer, U., Maurel, P., Lumbroso, S., Vilarem, M. J., and Pascussi, J. M. (2010). Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). *Endocrinology* **151**(4), 1653-1661.

DeKeyser, J. G., Laurenzana, E. M., Peterson, E. C., Chen, T., and Omiecinski, C. J. (2011). Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. *Toxicol. Sci.* **120**(2), 381-391.

di Masi A., De Marinis E., Ascenzi, P., and Marino, M. (2009). Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. *Mol. Aspects Med.* **30**(5), 297-343.

Diekema, D. J., Pfaller, M. A., Schmitz, F. J., Smayevsky, J., Bell, J., Jones, R. N., Beach, M., and SENTRY Participants Group (2001). Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis.* **32**(Suppl 2), S114-S132.

Eastman Kodak Co., Rochester, N., Environmental Protection Agency, and Office of Toxic Substances. Basic Toxicity of 4-Methoxy-1-Naphthol with Cover Letter. 8EHQ-0992-10994. 9-8-1992. <http://cfpub.epa.gov>

Evans, R. M. (2005). The nuclear receptor superfamily: a rosetta stone for physiology. *Mol. Endocrinol.* **19**(6), 1429-1438.

Faucette, S. R., Sueyoshi, T., Smith, C. M., Negishi, M., Lecluyse, E. L., and Wang, H. (2006). Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. *J. Pharmacol. Exp. Ther.* **317**(3), 1200-1209.

Gotoh, Y., Doi, A., Furuta, E., Dubrac, S., Ishizaki, Y., Okada, M., Igarashi, M., Misawa, N., Yoshikawa, H., Okajima, T., Msadek, T., and Utsumi, R. (2010). Novel antibacterial compounds specifically targeting the essential WalR response regulator. *J. Antibiot. (Tokyo)* **63**(3), 127-134.

Guo, G. L., Lambert, G., Negishi, M., Ward, J. M., Brewer, H. B., Jr., Kliewer, S. A., Gonzalez, F. J., and Sinal, C. J. (2003). Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. *J. Biol. Chem.* **278**(46), 45062-45071.

Howdeshell, K. L., Furr, J., Lambright, C. R., Rider, C. V., Wilson, V. S., and Gray, L. E. Jr. (2007). Cumulative effects of dibutyl phthalate and diethylhexyl phthalate on male rat reproductive tract development: altered fetal steroid hormones and genes. *Toxicol. Sci.* **99**(1), 190-202.

Ihunnah, C. A., Jiang, M., and Xie, W. (2011). Nuclear receptor PXR, transcriptional circuits and metabolic relevance. *Biochim. Biophys. Acta* **1812**(8), 956-963.

Istrate, M. A., Nussler, A. K., Eichelbaum, M., and Burk, O. (2010). Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding. *Biochem. Biophys. Res. Commun.* **393**(4), 688-693.

Ivanovic, J., Nicastrì, E., Ascenzi, P., Bellagamba, R., De, M. E., Notari, S., Pucillo, L. P., Tozzi, V., Ippolito, G., and Narciso, P. (2008). Therapeutic drug monitoring in the management of HIV-infected patients. *Curr. Med. Chem.* **15**(19), 1925-1939.

Jeffres, M. N., Isakow, W., Doherty, J. A., McKinnon, P. S., Ritchie, D. J., Micek, S. T., and Kollef, M. H. (2006). Predictors of mortality for methicillin-resistant *Staphylococcus aureus* health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. *Chest* **130**(4), 947-955.

Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C., Lecluyse, E. L., Lambert, M. H., Willson, T. M., Kliewer, S. A., and

Moore, J. T. (2000). The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. *Mol Endocrinol.* **14**(1), 27-39.

Jung, Y. J., Koh, Y., Hong, S. B., Chung, J. W., Ho Choi, S., Kim, M. N., Choi, I. S., Han, S. Y., Kim, W. D., Yun, S. C., and Lim, C. M. (2010). Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant *Staphylococcus aureus* pneumonia. *Crit Care Med.* **38**(1), 175-180.

Kliwer, S. A., Goodwin, B., and Willson, T. M. (2002). The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. *Endocr. Rev.* **23**(5), 687-702.

Kuroda, M., Ohta, T., Uchiyama, I., Baba, T., Yuzawa, H., Kobayashi, I., Cui, L., Oguchi, A., Nagai, Y., Lian, J., Ito, T., Kanamori, M., Matsumaru, H., Maruyama, A., Murakami, H., Hosoyama, A., Mizutani-Ui, Y., Takahashi, N. K., Sawano, T., Inoue, R., Kaito, C., Sekimizu, K., Hirakawa, H., Kuhara, S., Goto, S., Yabuzaki, J., Kanehisa, M., Yamashita, A., Oshima, K., Furuya, K., Yoshino, C., Shiba, T., Hattori, M., Ogasawara, N., Hayashi, H., and Hiramatsu, K. (2001). Whole genome sequencing of methicillin-resistant *Staphylococcus aureus*. *Lancet.* **357**(9264), 1225-1240.

Lamba, J. K., Lamba, V., Yasuda, K., Lin, Y. S., Assem, M., Thompson, E., Strom, S., and Schuetz, E. (2004). Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. *J. Pharmacol. Exp. Ther.* **311**(2), 811-821.

Lecluyse, E. L. (2001). Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. *Chem Biol Interact.* **134**(3), 283-289.

Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., and Kliwer, S. A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J. Clin. Invest* **102**(5), 1016-1023.

Lemaire, G., Benod, C., Nahoum, V., Pillon, A., Boussioux, A. M., Guichou, J. F., Subra, G., Pascussi, J. M., Bourguet, W., Chavanieu, A., and Balaguer, P. (2007). Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. *Mol. Pharmacol.* **72**(3), 572-581.

Lemaire, G., Mnif, W., Pascussi, J. M., Pillon, A., Rabenoelina, F., Fenet, H., Gomez, E., Casellas, C., Nicolas, J. C., Cavailles, V., Duchesne, M. J., and Balaguer, P. (2006). Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. *Toxicol. Sci.* **91**(2), 501-509.

Livak, KJ., and Schmittgen, TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods.* **25**(4), 402-408.

Ma, X., Idle, J. R., and Gonzalez, F. J. (2008). The pregnane X receptor: from bench to bedside. *Expert. Opin. Drug Metab Toxicol.* **4**(7), 895-908.

Ma, X., Shah, Y., Cheung, C., Guo, G. L., Feigenbaum, L., Krausz, K. W., Idle, J. R., and Gonzalez, F. J. (2007). The Pregnane X Receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. *Drug Metab Dispos.* **35**(2), 194-200.

Maglich, J. M., Parks, D. J., Moore, L. B., Collins, J. L., Goodwin, B., Billin, A. N., Stoltz, C. A., Kliewer, S. A., Lambert, M. H., Willson, T. M., and Moore, J. T. (2003). Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J. Biol. Chem.* **278**(19), 17277-17283.

Mo, S. L., Liu, Y. H., Duan, W., Wei, M. Q., Kanwar, J. R., and Zhou, S. F. (2009). Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. *Curr. Drug Metab* **10**(7), 730-753.

Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., Collins, J. L., and Kliewer, S. A. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. *J. Biol. Chem.* **275**(20), 15122-15127.

Moreau, A., Vilarem, M. J., Maurel, P., and Pascussi, J. M. (2008). Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. *Mol. Pharm.* **5**(1), 35-41.

Nakajima, A., Fukami, T., Kobayashi, Y., Watanabe, A., Nakajima, M., and Yokoi, T. (2011). Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. *Biochem Pharmacol.* **82**(11), 1747-1756.

Omicinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., and Peters, J. M. (2011). Xenobiotic Metabolism, Disposition, and Regulation by Receptors: From Biochemical Phenomenon to Predictors of Major Toxicities. *Toxicol. Sci.* **120**(Suppl 1), S49-S75.

Pascussi, J. M., and Vilarem, M. J. (2008). [[Inflammation and drug metabolism: NF-kappB and the CAR and PXR xeno-receptors]. *Med. Sci. (Paris)* **24**(3), 301-305.

Perlroth, J., Kuo, M., Tan, J., Bayer, A. S., and Miller, L. G. (2008). Adjunctive use of rifampin for the treatment of *Staphylococcus aureus* infections: a systematic review of the literature. *Arch Intern Med.* **168**(8), 805-819.

Rae, J. M., Johnson, M. D., Lippman, M. E., and Flockhart, D. A. (2001). Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. *J Pharmacol Exp Ther.* **299**(3), 849-857.

Rello, J., Torres, A., Ricart, M., Valles, J., Gonzalez, J., Artigas, A., and Rodriguez-Roisin, R. (1994). Ventilator-associated pneumonia by *Staphylococcus aureus*. Comparison of methicillin-resistant and methicillin-sensitive episodes. *Am J Respir Crit Care Med.* **150**(6 Pt 1), 1545-1549.

Savkur, R. S., Wu, Y., Bramlett, K. S., Wang, M., Yao, S., Perkins, D., Totten, M., Searfoss, G., III, Ryan, T. P., Su, E. W., and Burris, T. P. (2003). Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. *Mol. Genet. Metab* **80**(1-2), 216-226.

Scheer, N., Ross, J., Kapelyukh, Y., Rode, A., and Wolf, W. C. (2010). In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. *Drug Metab Dispos.* **38**(7), 1046-1053.

Schippers, I. J., Moshage, H., Roelofsen, H., Muller, M., Heymans, H. S., Ruiters, M., and Kuipers, F. (1997). Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation. *Cell Biol. Toxicol.* **13**(4-5), 375-386.

Shoji, O., Wiese, C., Fujishiro, T., Shirataki, C., Wunsch, B., and Watanabe, Y. (2010). Aromatic C-H bond hydroxylation by P450 peroxygenases: a facile colorimetric assay for monooxygenation activities of enzymes based on Russig's blue formation. *J. Biol. Inorg. Chem.* **15**(7), 1109-1115.

Siest G., Jeannesson E., Marteau JB., Samara A., Marie B., Pfister M., and Visvikis-Siest S. (2008). Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. *Drug Metab Dispos.* **36**(1), 182-189.



Siest, G., Jeannesson, E., Marteau, JB., Samara, A., Marie, B., Pfister, M., and Visvikis-Siest, S. (2008). Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. *Drug Metab Dispos.* **36**(1), 182-189.

Singh, M., Sasi, P., Rai, G., Gupta, V. H., Amarapurkar, D., and Wangikar, P. P. (2011). Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line. *Med. Chem. Res.* **20**, 1611-1615.

Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., and Negishi, M. (1999). The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. *J. Biol. Chem.* **274**(10), 6043-6046.

Talaat, R. E., and Nelson, W. L. (1986). Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)lactic acid as a metabolite of propranolol in the rat, in man, and in the rat liver 9000 g supernatant fraction. *Drug Metab Dispos.* **14**(2), 202-207.

Timsit, Y. E., and Negishi, M. (2007). CAR and PXR: the xenobiotic-sensing receptors. *Steroids* **72**(3), 231-246.

Wada, T., Gao, J., and Xie, W. (2009). PXR and CAR in energy metabolism. *Trends Endocrinol. Metab* **20**(6), 273-279.

Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., Willson, T. M., Kliewer, S. A., and Redinbo, M. R. (2001). The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. *Science* **292**(5525), 2329-2333.

Xie, W., Yeuh, M. F., Radominska-Pandya, A., Saini, S. P., Negishi, Y., Bottroff, B. S., Cabrera, G. Y., Tukey, R. H., and Evans, R. M. (2003). Control of steroid, heme, and

carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. *Proc. Natl. Acad. Sci. U. S. A* **100**(7), 4150-4155.

### Legends

**Figure 1: Walrycin A regulates mRNA expression of a large set of drug metabolism phase I enzymes.**

**A:** Structure of the tested compounds. **B:** Scatter plot of mRNA expression upon walrycin A treatment ( $2^{-\Delta C_t}$  (walrycin A)) compared to vehicle treatment ( $2^{-\Delta C_t}$  (DMSO)). Upregulated (>4 fold change), not deregulated ( $-4 < \text{fold change} < 4$ ) and downregulated (>-4 fold change) gene expression are displayed within dark gray, central uncolored and light gray areas, respectively. **C:** Phase I enzymes differentially expressed in response to walrycin A treatment (fold-change>4). The gene list was clustered in 3 main families (alcohol dehydrogenase, aldehyde dehydrogenase and cytochrome p450). Enzymes not belonging to these 3 main families are labeled as “others”.

**Figure 2: Dose-dependence activation of CYP3A4 by walrycin A is PXR-dependent.**

**A:** IHH cells were treated for 24h with indicated concentrations of rifampicin (black bar). Expression of *CYP3A4* was determined by qPCR, normalized to *RPLP0* expression level and compared to DMSO control (white bar). Histograms represent means  $\pm$  SEM of a representative experiment performed in triplicate. **B:** Cells were treated for 24h with indicated concentrations of walrycin A (black bar) or 6MNol (hatched bar). Expression of *CYP3A4* was determined by qPCR and analyzed as described above. Histograms represent means  $\pm$  SEM of 3 independent experiments performed with triplicates. Statistical significances were determined with a Dunnett's Multiple Comparison Test (\*\*\* $p < 0.001$ ). **C:** Cells were

transfected with control siRNA (white bars) or by PXR-targeting siRNA (black bars) and knock-down expression of *PXR* gene (mRNA and protein) was assessed by qPCR and western blot analysis. **D:** Control and PXR-targeting siRNA transfected cells were treated 24h by vehicle (0.1% DMSO), rifampicin or walrycin A. The expression of *PXR* and *CYP3A4* was determined by qPCR, normalized to *RPLP0* expression level and expressed relative to that detected in cells transfected by control siRNA. Histograms represent means  $\pm$  SEM of a representative experiment performed in triplicate. Statistical significances were determined using a Bonferroni post-hoc test (\*\* $p < 0.001$  and \*\* $p < 0.01$ ).

**Figure 3: Walrycin A induces conformational changes in the human PXR receptor polypeptide.**

*In vitro* translation of hPXR was carried out in the presence of 0.1% DMSO, 50 $\mu$ M 6MNol, walrycin A or rifampicin. Upon completion of protein synthesis, limited proteolysis assay was performed as described in materials and methods using varying concentrations of chymotrypsin (up to 5  $\mu$ g/mL). Radio-labeled peptides were detected using a Phosphorimager system. Arrow indicates the short fragments corresponding to LBD of PXR partially protected from digestion in presence of rifampicin or walrycin A.

**Figure 4: Walrycin A activates PXR through its ligand binding domain.**

HeLa cell line in which a chimeric GAL4-DBD-PXR LBD fusion protein was stably expressed was treated with DMSO (negative control), SR12813 (positive control), walrycin A or 6MNol. **A:** Cells were treated with increasing concentrations of walrycin A ranging from 0.5  $\mu$ M to 200  $\mu$ M. **B:** Cells were treated with 150  $\mu$ M of walrycin A or 6MNol. All experiments were performed in duplicates and results were plotted compared to maximal luciferase activity obtained using 1  $\mu$ M of SR12813 (100% of transactivation).

**Figure 5: The walrycin A oxidation product Russig's blue fits in PXR ligand-binding pocket.**

**A:** Images of docking solutions for SR12813, Russig's blue, Walrycin A and 6MNol in PXR ligand-binding domain from 3HVL. Endogenous 3HVL SR12813 ligand is shown in magenta and three solutions for each ligand are shown in gold. Oxygen atoms are shown in red except in the reference ligand (magenta). **B:** Ligand fitting in 3HVL and 1ILH ligand-binding pockets as assessed with GOLD (Chemscore, good fitting results in high score) and FRED (FRED score, good fitting results in low score). Russig's blue and SR12813 grouped as best fitting compounds compared to walrycin A and 6MNol.

**Figure 6: Impacts of rifampicin and Walrycin A on hepatoma cell viability.**

**A:** HepG2 cells were treated for 24h using compounds concentrations ranging from 2  $\mu$ M to 5 mM for walrycin A and from 0.5  $\mu$ M to 1mM for rifampicin. Data were normalized using DMSO as internal control. Rifampicin: black curve, walrycin A: gray curve. **B:** Cells were treated for 24h and 48h using 100  $\mu$ M rifampicin (black bars), 50  $\mu$ M walrycin A (gray bars) or treated in combination with rifampicin 100  $\mu$ M and walrycin A 50  $\mu$ M (white bars). Data were normalized using DMSO as internal control. Histograms represent means  $\pm$  SEM of a representative experiment performed in quadruplicate. Statistical significances were determined with a Dunnett's Multiple Comparison Test (\*\*p<0.01).